false 0001867066 0001867066 2024-04-26 2024-04-26 iso4217:USD xbrli:shares iso4217:USD xbrli:shares













Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): April 26, 2024


Journey Medical Corporation

(Exact Name of Registrant as Specified in Charter)


Delaware  001-41063  47-1879539
(State or Other Jurisdiction
of Incorporation)
  (Commission File Number)  (I.R.S. Employer Identification No.)


9237 E Via de Ventura Blvd., Suite 105

Scottsdale, AZ 8525

(Address of principal executive offices)


Registrant’s telephone number, including area code: (480) 434-6670


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange
on which registered
Common Stock DERM The Nasdaq Capital Market


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company   x


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨







Item 5.02.Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On April 26, 2024, the Board of Directors (the “Board”) of Journey Medical Corporation (the “Company”) appointed Joseph Benesch, age 57, as the Company’s permanent Chief Financial Officer. As previously disclosed in the Company’s Current Report on Form 8-K filed with the SEC on January 20, 2023, the Board appointed Mr. Benesch as the Company’s interim Chief Financial Officer, effective January 27, 2023, and such disclosure is hereby incorporated by reference.


Mr. Benesch’s compensation has not changed as a result of this appointment. Any changes to Mr. Benesch’s compensation package, if any, will be determined by the Company’s Board upon recommendation of its Compensation Committee.


No family relationships exist between Mr. Benesch and any of the Company’s directors or other executive officers. There are no arrangements or understandings between Mr. Benesch and any other person pursuant to which Mr. Benesch was selected as the Company’s Chief Financial Officer, nor are there any transactions to which the Company is or was a participant and in which Mr. Benesch has a material interest subject to disclosure under Item 404(a) of Regulation S-K.


Item 8.01.Other Events.


On May 1, 2024, the Company issued a press release announcing the appointment of Mr. Benesch as permanent Chief Financial Officer. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.


Item 9.01.Financial Statements and Exhibits.


(d) Exhibits.


The following exhibits are furnished herewith:


99.1   Press release issued by Journey Medical Corporation, dated May 1, 2024.
104   Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL).







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Journey Medical Corporation
 By:/s/ Claude Maraoui
  Claude Maraoui
  Chief Executive Officer, President and Director
Date: May 1, 2024